Industry ranking
Moderna Biotech Manufacturing UK Ltd carries an average payment time of 43 days, sitting 13 days beyond standard 30-day terms and indicating a consistent pattern of delayed settlement. The majority of payments (52%) fall within the 31–60 day band, suggesting that late payment is the operational norm rather than an exception. Only 40% of invoices are cleared within agreed terms, pointing to a structural payment cycle that runs longer than contracted.
With 8% of payments exceeding 60 days and a reported late payment rate of 9%, the company presents a moderate but manageable risk profile, with a small but notable tail of significantly delayed settlements. Payment behaviour is relatively predictable in that most invoices cluster in the 31–60 day window, reducing the likelihood of extreme outlier delays, though suppliers should not rely on on-time payment as a baseline. The consistency of the pattern across bands suggests this is an embedded process issue rather than isolated cash flow stress.
Suppliers considering extended credit terms with Moderna Biotech Manufacturing UK Ltd should treat 45–50 days as the realistic effective payment cycle rather than the stated 30-day terms. The risk level is moderate; the company is unlikely to default but will routinely pay late, making cash flow planning essential for smaller suppliers. It is advisable to negotiate payment terms of net 45 days contractually, apply prompt payment incentives if margin allows, and review aged debt regularly to catch the 8% of invoices at risk of exceeding 60 days.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 02 Feb 2026 | 43 | 40% | 52% | 8% | 9% |
| 01 Jan 2025 - 30 Jun 2025 | 30 Jul 2025 | 59 | 19% | 66% | 15% | 21% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Net 60 for regular companies, Net 0 for healthcare professionals, government entities, insurance companies. These payment terms apply unless specifically stated in the agreement or the SOW.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
0
In case of unpaid invoice – supplier contacts accountspayable@modernatx.com who is responsible for payment terms verification and preparing payment as soon as possible In case of quality/quantity/price difference – invoice is rejected back to supplier’s contact address by Accounts Payable based on order owner’s comment with a standard notification (wording may be slightly different depending on rejection reason): Dear Supplier, please be informed that your invoice has been rejected by order owner due to quality/quantity/price difference. Please contact your Moderna Business Contact to explain the difference. Amended invoice please resubmit to invoice@modernatx.com. Thank you for your understanding. Kind Regards, Moderna Accounts Payable Team
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Moderna Biotech Manufacturing UK Ltd is a UK registered company incorporated in June 2022, forming part of the Moderna biotechnology group. Its stated business activities cover the manufacture of basic pharmaceutical products and pharmaceutical preparations. It holds a Human Tissue Authority licence for a premises used in research, with licensed activities including storage of relevant material. The company is registered in London and remains active, with its officers based in the UK and the United States, reflecting its role within a wider international corporate structure rather than as an independent standalone manufacturer.
Generated from the company's website and Companies House records. Sources: find-and-update.company-information.service.gov.uk · hta.gov.uk